- Trials with a EudraCT protocol (104)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
104 result(s) found for: Cell membrane.
Displaying page 1 of 6.
EudraCT Number: 2022-001585-36 | Sponsor Protocol Number: AMC_SMILE_1.0 | Start Date*: 2022-07-05 | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial) | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004419-11 | Sponsor Protocol Number: SC35 | Start Date*: 2017-04-20 | ||||||||||||||||
Sponsor Name:Radboud university medical center | ||||||||||||||||||
Full Title: Safety and efficacy of interleukin-1 inhibitor anakinra for the amelioration of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem c... | ||||||||||||||||||
Medical condition: Mucositis and febrile neutropenia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001543-19 | Sponsor Protocol Number: CSCTversion1.2 | Start Date*: Information not available in EudraCT |
Sponsor Name:Antwerp University Hospital (UZA) | ||
Full Title: Cultivated Limbal Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency. | ||
Medical condition: Patients suffering from Limbal Stem Cell Deficiency will be investigated during the course of this clinical trial. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001039-29 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-01 | |||||||||||
Sponsor Name:HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS | |||||||||||||
Full Title: EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL | |||||||||||||
Medical condition: Organ dysfunction by the novel SARS-Cov-2 virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005427-16 | Sponsor Protocol Number: D4191C00003 | Start Date*: 2014-07-22 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have receive... | ||||||||||||||||||
Medical condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) BE (Trial now transitioned) AT (Completed) ES (Completed) PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001375-21 | Sponsor Protocol Number: D419AC00002 | Start Date*: 2018-06-28 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Express... | |||||||||||||
Medical condition: First line patients with Advanced Non Small-Cell Lung Cancer (NSCLC) with PD-L1 positive membrane expression in tumoral tissue and lacking activating epdermal growth factor receptor (EGFR) mutation... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001193-15 | Sponsor Protocol Number: FASTERCC-001 | Start Date*: 2016-07-06 | |||||||||||||||||||||||||||||||
Sponsor Name:Department of Oncology, Aarhus University Hospital | |||||||||||||||||||||||||||||||||
Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ... | |||||||||||||||||||||||||||||||||
Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001927-74 | Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) | Start Date*: 2009-01-16 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES... | ||
Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
Sponsor Name:AMsterdam UMC-AMC | ||
Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000174-25 | Sponsor Protocol Number: 101090401IN | Start Date*: 2023-03-17 | |||||||||||
Sponsor Name:SANTEN INCORPORATED | |||||||||||||
Full Title: A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehi... | |||||||||||||
Medical condition: Fuchs Endothelial Corneal Dystrophy (FECD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001747-21 | Sponsor Protocol Number: ISPUP2020CT1 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Instituto de Saúde Pública Universidade Porto | |||||||||||||
Full Title: Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial | |||||||||||||
Medical condition: Novel coronavirus pneumonia (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002082-38 | Sponsor Protocol Number: RG_11-123 | Start Date*: 2012-04-16 |
Sponsor Name:University of Birmingham | ||
Full Title: A study of the effects of Simvastatin on neutrophil function in elderly subjects | ||
Medical condition: We are investigating the effects of Simvastatin 80mg on neutrophil function (using in vitro studies of neutrophil function), in healthy elderly subjects as there is evidence to suggest that Simvast... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-006664-29 | Sponsor Protocol Number: cro955 | Start Date*: 2008-02-26 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: The effect of inhaled corticosteroids (ICS) on airway smooth muscle in asthma | |||||||||||||
Medical condition: Asthma is a disease characterised by reversible airways obstruction, bronchial hyper-responsiveness (BHR), and chronic inflammation of the bronchial mucosal lining. Structural changes in the airwa... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002601-40 | Sponsor Protocol Number: CD20-0703 | Start Date*: 2008-09-25 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: Open, non-controlled, multicentre, first-in-man study using escalating doses of LFB-R603 in patients with advanced stage B-Chronic lymphocytic leukemia | |||||||||||||
Medical condition: B-Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006646-12 | Sponsor Protocol Number: POMAlternative | Start Date*: 2024-04-25 |
Sponsor Name:Amsterdam UMC | ||
Full Title: Alternative dosing scheme of pomalidomide 4 mg every other day versus pomalidomide 2 mg and 4 mg every day: reduction in costs, same efficacy? A PKPD bioequivalence pilot study. | ||
Medical condition: Multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003715-38 | Sponsor Protocol Number: D4190C00006 | Start Date*: 2016-05-12 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:MedImmune LLC | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004342-42 | Sponsor Protocol Number: 201302 | Start Date*: 2014-03-26 | |||||||||||
Sponsor Name:Medisch Centrum Alkmaar | |||||||||||||
Full Title: The effect of fish oil supplements on hemorheological parameters and walking distance in patients with intermittent claudication | |||||||||||||
Medical condition: Patients suffering from intermittent claudication | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002130-30 | Sponsor Protocol Number: NSCLC-TKD/IL-2 | Start Date*: 2013-11-15 | |||||||||||
Sponsor Name:Technische Universität München Fakultät für Medizin | |||||||||||||
Full Title: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) | |||||||||||||
Medical condition: Interventional phase II clinical trial incorporating a parallel control group of patients receiving no adjuvant immunotherapy. Patients with non small lung cell carcinoma (NSCLC) in stage III A and... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019991-55 | Sponsor Protocol Number: CC-10004-PSOR-008 | Start Date*: 2011-01-25 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003438-18 | Sponsor Protocol Number: AG-348inSCD | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:Julius Clinical | |||||||||||||
Full Title: Evaluation of safety and efficacy in mitapivat sulfate in adult patients with sickle cell disease | |||||||||||||
Medical condition: Sickle cell disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
